Edwards Lifesciences Corporation EW
Healthcare · Medical Devices · United States · S&P 500
Based on the available data, Edwards Lifesciences Corporation gets an algorithmic score of 62/100. It trades at 88.08 $, with a bullish technical trend (RSI 50.3) and 25.2% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- Sustained revenue growth (10.8% compound annual).
- Low-debt balance sheet.
- Low beta (0.63): defensive profile.
Weaknesses
- —
Fundamentals
| P/E | 52.43 |
| Forward P/E | 26.08 |
| PEG | 1.85 |
| P/B | 4.78 |
| EV/EBITDA | 23.70 |
| P/S | 7.79 |
| ROE % | 9.18 |
| ROA % | 8.37 |
| Gross margin % | 77.84 |
| Operating margin % | 29.84 |
| Net margin % | 15.43 |
| Revenue growth % (y/y) | 13.60 |
| Earnings growth % (y/y) | -25.40 |
| Revenue CAGR % | 10.77 |
| Earnings CAGR % | -10.98 |
| Debt/Equity % | 6.57 |
| Current ratio | 4.52 |
| FCF yield % | 2.63 |
| Dividend yield % | 0.00 |
| Payout % | 0.00 |
Returns
| 1 month | -2.4 % |
| 3 months | -2.6 % |
| 6 months | +10.8 % |
| YTD | +3.2 % |
| 1 year | +15.5 % |
| 3 years | +26.4 % |
| 5 years | -25.7 % |
Risk
| 1-year volatility | 25.2 % |
| Beta | 0.63 |
| 5-year max drawdown | -54.3 % |
| Sharpe 1A | 0.54 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.